Изменения в легких вследствие лекарственной терапии больных лимфомой Ходжкина


https://doi.org/10.18093/0869-0189-2013-0-1-95-100

Полный текст:


Аннотация

Изменения в легких вследствие лекарственной терапии больных лимфомой Ходжкина.


Об авторах

А. А. Даниленко
ФГБУ "Медицинский радиологический научный центр" Минздрава РФ
Россия

к. м. н., старший научный сотрудник

249036, Калужская область, г. Обнинск, ул. Королева, 4



С. В. Шахтарина
ФГБУ "Медицинский радиологический научный центр" Минздрава РФ
Россия

д. м. н., ведущий научный сотрудник

249036, Калужская область, г. Обнинск, ул. Королева, 4



Список литературы

1. Meadors M., Floyd J., Perry M.C. Pulmonary toxicity of chemotherapy. Semin. Oncol. 2006; 33 (1): 98–105.

2. Bredenfeld H., Franklin J., Nogova L. et al. Severe pulmonary toxicity in patients with advanced–stage Hodgkin`s disease treated with modified bleomycin, doxorubicin, cyclophosfamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin`s Lymphoma Study Group. J. Clin. Oncol. 2004; 22: 2424–2429.

3. Torrisi J.M., Schwartz L.H., Gollub M.J. CT findings of chemotherapy–induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 2011; 258 (1): 41–56.

4. Даниленко А.А., Шахтарина С.В., Афанасова Н.В. и др. Изменения в легких у больных лимфомой Ходжкина после химиотерапии по схемам СОРР, ABVD, BEACOPP и облучения средостения в суммарной очаговой дозе 20–30 Гр. Клин. Онкогематол. 2010; 3 (4): 354–358.

5. Roig J. Pulmonary toxicity caused by cytotoxic drugs. Clin. Pulm. Med. 2006; 13 (1): 53–62.

6. Umezawa H., Meaeda K., Takeuchi T. et al. New antibiotics, bleomycin A and B. J. Antibiot. Ser. A. 1966; 19: 200–2005.

7. Martin W.G., Ristow K.M., Habermann T.M. et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin`s lymphoma. J. Clin. Oncol. 2005; 23: 7614–7620.

8. Ohnuma T., Holland J.F., Masuda h. et al. Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance. Cancer (Philad.) 1974; 33: 1230–1238.

9. Santrack P.J., Askin F.B., Wells R.J. et al. Nodular form of bleomycin–related pulmonary injury in patients with osteogenic sarcoma. Cancer (Philad.) 1989; 64: 806–811.

10. Holoye P.Y., Luna M.H., Mackay B. et al. Bleomycin hypersensitivity pneumonitis. Ann. Intern. Med. 1978; 88: 47–49.

11. Vender Els N.J., Stover D.E. Chemotherapy–induced lung disease. Clin. Pulm. Med. 2004; 11 (2): 84–91.

12. Jules–Elysee K., White D.A. Bleomycin–induced pulmonary toxicity. Clin. Chest Med. 1990; 11: 1–20.

13. Simpson A.B., Paul J., Graham J. et al. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991–95: a review of patients with germ cell tumours. Br. J. Cancer 1998; 78: 1061–1066.

14. Burger R.M., Pesach J., Horwitc S.B. Activated bleomycin: a transient complex of drug, iron and oxygen that degradates DNA. J. Biol. Chem. 1981; 256: 1636–1644.

15. Schirner M., Hoffmann J., Menrad A. et al. Antiangiogenetic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin. Cancer. Res. 1998; 4: 1331–1336.

16. Adamson I.j.R., Bowden D.H. The pathogebesis of bleomycine–induced pulmonary fibrosis in mice. Am. J. Pathol. 1974; 77: 185–191.

17. Van Barneveld P.W.C., Sleijfer D.T., Van der Mark T.W. et al. The natural course of bleomycin induced pneumonitis (BIP): a follow–up study in eight patients. Am. Rev. Respir. Dis. 1987; 135: 48–51.

18. Piguet P.F. Cytokines involved in pulmonary fibrosis. Int. Rev. Exp. Pathol.1993; 34: 173–181.

19. Hagimoto N., Kuwano K., Nomoto Y. et al. Apoptosis and expression of Fas / Fas ligand mRNA in bleomycin–induced pulmonary fibrosis in mice. Am. J. Respir. Cell. Mol. Biol. 1997; 16: 91–101.

20. Kuwano K., Hagimoto N., Kawasaki M. et al. Essential roles of the Fas / Fas ligand pathway in the development of pulmonary fibrosis. J. Clin. Invest. 1999; 104: 13–19.

21. Phan S.H., Kunkel S.L. Lung cytocine production in bleomycin–induced pulmonary fibrodsis. Exp. Lung Res. 1992; 18: 29–43.

22. Santana A., Saxena B., Noble N.A. et al. Increased expression of transforming growth factor β isoforms (β1, β2, β3) in bleomycin–induced pulmonary fibrosis. Am. J. Respir. Cell. Mol. Biol. 1995; 13: 34–44.

23. Doelman C.J.A., Bast A. Oxygen radicals in lung pathology. Free Radic. Biol. Med. 1990; 9: 381–400.

24. Herman E.H., Hasinoff B.B., Zhang J. et al. Morphologic and morphometric evaluation of the effect of ICRF–187 on bleomycin–induced pulmonary toxicity. Toxicology 1995; 98: 163–175.

25. Nici L., Calabresi P. Amifostine modulation of bleomycin–induced lung injury in rodents. Semin. Oncol. 1999; 26: 28–33.

26. Moseley P.L., Hemken C., Hunninghake G.W. Augmentation of fibroblast proliferation by bleomycin. J. Clin. Invest.1986; 78: 1150–1154.

27. Schmidt J.A., Mizel S.B., Cohen D. et al. Interleukin–1: a potential regulator of fibroblast proliferation. J. Immunol. 1982; 128: 2177–2182.

28. Sugerman B.J., Aggarval B.B., Figary I.S. et al. Recombinant human tumor necrosis factor β: effects on proliferation of normal and transformed cells in vitro. Science 1985; 230: 943–945.

29. Zhang K., Flanders K.C., Phan S.H. Cellular localization of transforming growth factor α expression in bleomycin–induced pulmonary fibrosis. Am. J. Pathol.1995; 147: 352–361.

30. Giri S.N., Hyde D.M., Hollinger M.A. Effect of antibody to transforming growth factor β on bleomycin induced accumulation of lung collagen in mice. Thorax 1993; 48: 959–966.

31. White D.A., Stover D.E. Severe bleomycin–induced pneumonitis: clinical features and response to corticosteroids. Chest 1984; 86: 723–728.

32. De Lena M., Guzzon A., Monfardini S. et al. Clinical, radiologic and histopathological studies on pulmonary toxicity induced by treatment with bleomycin. Cancer Chemother. Rep. 1972; 56: 343–355.

33. Ngeow J., Tan I.B., Kanesvaran R. et al. Prognostic impact of bleomycin–induced pneumonitis on the outcome of Hodgkin`s lymphoma. Ann. Hematol. 2011; 90 (1): 67–72.

34. Yagoda A., Makherji B., Young C. et al. Bleomycin: an antitumor antibiotic; clinical experience in 274 patients. Ann. Intern. Med.1972; 77 (6): 861–870.

35. Flieder D.B., Travis W.D. Pathologic characteristics of drug–induced lung disease. Clin. Chest Med. 2004; 25 (1): 37–45.

36. Comis R.L., Kuppinder M.S., Ginsberg S.J. et al. Bleomycin–induced pulmonary function abnormalities. Cancer Res. 1979; 39 (12): 5076–5080.

37. Wolkowicz J., Sturgeon J., Ravji M. et al. Bleomycin–induced pulmonary function abnormalities.Chest 1992; 101: 97–101.

38. Sorensen P.G., Rossing N., Roth M. Carbon monoxide diffusing capacity: a reliable indicator of bleomycin–induced pulmonary toxicity. Eur. J. Respir. Dis. 1985; 66: 333–340.

39. Sleijfer S., van der Mark T.W., Schafford Koops H. et al. Decrease in pulmonary function during bleomycin–containing combination chemotherapy for testicular cancer: not only a bleomycin effect. Br. J. Cancer 1995; 71 (1): 120–123.

40. Hirsch A., Vander Els N., Straus D.J. et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early–stage Hodgkin`s disease. J. Clin. Oncol. 1996; 14: 1297–1305.

41. Collis C.H. Lung damage of cytotoxic drugs. Cancer Chemother. Pharmacol. 1980; 4: 17–27.

42. McLeod B.F., Lawrence H.J., Smith D.W. et al. Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency. Cancer (Philad.) 1987; 60: 2617–2622.

43. Bauer K.A., Skarin A.T., Balikian J.P. et al. Pulmonary complications associated with combination chemotherapy programs containing bleomycin. Am. J. Med. 1983; 74: 557–563.

44. Lower E.E., Strohofer S., Baughman R.P. Bleomycin causes alveolar macrophages from cigarette smokers to release hydrogen peroxide. Am. J. Med. Sci. 1988; 295: 193–197.

45. Crooke S.T., Comis R.L., Einhorn L.H. et al. Effect of variations in renal function on the clinical pharmacology of bleomycin administrated as an iv bolus. Cancer Treat. Rep.1977; 61: 1631–1636.

46. Hall S.W., Strong J.E. Broughton A. et al. Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother. Pharmacol. 1982; 9: 22–25.

47. Sleijfer S., van der Mark T.W., Schraffordt Koops H. et al. Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin. Eur. J. Cancer 1996; 32 (3): 550–552.

48. Horning S.J., Adhikari A., Rizk N. et al. Effect of treatment for Hodgkin`s disease on pulmonary function: results of a prospective study. J. Clin. Oncol. 1994; 12: 297–305.

49. Macann A., Bredenfeld H., Muller R.P. et al. Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced–stage Hodgkin`s lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin`s Lymphoma Study Group. Int. J. Radiat. Oncol. Biol. Phys. 2008; 70: 161–165.

50. Sogal R.N., Gottlieb A.A., Boutros A.R. et al. Effect of oxygen on bleomycin–induced lung damage. Cleveland Clin. J. Med. 1987; 54: 503–509.

51. Tryka A.F., Skornik W.A., Godleski J.J. et al. Potentiation of bleomycin–induced lung injury by exposure to 70 % oxygen. Am. Rev. Respir. Dis. 1982; 126: 1074–1076.

52. Matthews J. Pulmonary toxicity of ABVD chemotherapy and G–CSF in Hodgkin's disease: possible synergy. Lancet 1993; 342: 988.

53. Saxman S.B., Nichols C.R., Einhorn L.H. Pulmonary toxicity in patients with advanced–stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating growth factor. Chest 1997; 111: 657–660.

54. Wedgwood A., Younes A. Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin`s lymphoma. Clin. Lymphoma Myeloma 2007; 8 (Suppl. 2): 63–66.

55. Piguet P.F., Vesin C., Grau G.E. et al. Interleukin 1 receptor antagonist (IL–Ira) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or cilica. Cytokine 1993; 5 (1): 57–61.

56. Sugahara K., Iyama K., Kuroda M.J. et al. Double intratracheal installation of keratinocyte growth factor prevents bleomycin–induced lung fibrosis in rats. J. Pathol. 1998; 186: 90–98.

57. Lossos I.S., Or R., Goldstein R.H. et al. Amelioration of bleomycin–induced pulmonary injury by cyclosporin A. Exp. Lung. Res. 1996; 22: 337–349.

58. Piguet P.F., Tacchini–Cottier F., Vesin C. Administration of anti–TNF–alpha or anti–CD11a antibodies to nirmal adult mice dicreases lung and bone collagen content: evidence for an effect on platelet consumption. Am. J. Respir. Cell. Mol. Biol. 1995; 12 (2): 227–231.

59. Sharma S.K., MacLean J.A., Pinto C. et al. The effect of an anti–CD3 monoclonal antibody on bleomycin induced lymphokine production and lung injury. Am. J. Respir. Dis. 1996; 154: 193–200.

60. Nettelbladt O., Tengblad A., Hallgren R. High–dose corticosteroids during bleomycin–induced alveolitis in the rat do not suppress the accumulation of hyaluronan (hyaluronic acid) in lung tissue. Eur. Respir. J. 1990; 3: 421–428.


Дополнительные файлы

Для цитирования: Даниленко А.А., Шахтарина С.В. Изменения в легких вследствие лекарственной терапии больных лимфомой Ходжкина.  Пульмонология. 2013;(1):95-100. https://doi.org/10.18093/0869-0189-2013-0-1-95-100

For citation: Danilenko A.A., Shakhtarina S.V. Pulmonary lesions due to drug therapy of Hodgkin's lymphoma. Russian Pulmonology. 2013;(1):95-100. (In Russ.) https://doi.org/10.18093/0869-0189-2013-0-1-95-100

Просмотров: 242

Обратные ссылки

  • Обратные ссылки не определены.


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)